147 related articles for article (PubMed ID: 31849389)
1. A case of advanced prostate cancer controlled for the long term by flutamide after bicalutamide failure.
Muramatsu T; Funahashi Y; Yamamoto A; Sassa N; Matsukawa Y; Gotoh M
Nagoya J Med Sci; 2019 Nov; 81(4):707-710. PubMed ID: 31849389
[TBL] [Abstract][Full Text] [Related]
2. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
3. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Control Trial Comparing the Efficacy of Antiandrogen Monotherapy: Flutamide vs. Bicalutamide.
Nakai Y; Tanaka N; Anai S; Miyake M; Tatsumi Y; Fujimoto K
Horm Cancer; 2015 Aug; 6(4):161-7. PubMed ID: 26024831
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer: Enzalutamide is superior to bicalutamide for mCRPC.
Sidaway P
Nat Rev Urol; 2016 Mar; 13(3):124. PubMed ID: 26832166
[No Abstract] [Full Text] [Related]
6. Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study.
Zhao JG; Liu JD; Shen PF; Tang X; Sun GX; Zhang XM; Chen JR; Shu KP; Shi M; Zeng H
Asian J Androl; 2018; 20(6):545-550. PubMed ID: 30106011
[TBL] [Abstract][Full Text] [Related]
7. Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancer.
Fukuoka K; Teishima J; Nagamatsu H; Inoue S; Hayashi T; Mita K; Shigeta M; Kobayashi K; Kajiwara M; Kadonishi Y; Tacho T; Matsubara A
Int Urol Nephrol; 2020 Jan; 52(1):77-85. PubMed ID: 31552574
[TBL] [Abstract][Full Text] [Related]
8. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Chen Y; Kolvenbag GJ
Cancer; 1996 Nov; 78(10):2164-9. PubMed ID: 8918410
[TBL] [Abstract][Full Text] [Related]
9. [Alternative antiandrogen therapy with flutamide in patients with castration-resistant prostate cancer : a single center experience].
Takada T; Ishizuya Y; Okada T; Ueda T; Inoue H; Hara T
Hinyokika Kiyo; 2011 Jun; 57(6):291-5. PubMed ID: 21795830
[TBL] [Abstract][Full Text] [Related]
10. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?
Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M; Penson D
Urology; 2005 Oct; 66(4):835-9. PubMed ID: 16230148
[TBL] [Abstract][Full Text] [Related]
11. Antiandrogen monotherapy in the management of advanced prostate cancer.
Kaisary AV
Eur Urol; 1997; 31 Suppl 2():14-9; discussion 24-7. PubMed ID: 9074906
[TBL] [Abstract][Full Text] [Related]
12. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
Blackledge G; Kolvenbag G; Nash A
Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095
[TBL] [Abstract][Full Text] [Related]
13. Antiandrogen monotherapy: recommendations for the treatment of prostate cancer.
Sciarra A; Cardi A; Di Silverio F
Urol Int; 2004; 72(2):91-8. PubMed ID: 14963347
[TBL] [Abstract][Full Text] [Related]
14. Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.
Schultz NM; Shore ND; Chowdhury S; Klotz LH; Concepcion RS; Penson DF; Karsh LI; Yang H; Brown BA; Barlev A; Flanders SC
BMC Urol; 2018 Sep; 18(1):77. PubMed ID: 30189902
[TBL] [Abstract][Full Text] [Related]
15. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
Scher HI; Liebertz C; Kelly WK; Mazumdar M; Brett C; Schwartz L; Kolvenbag G; Shapiro L; Schwartz M
J Clin Oncol; 1997 Aug; 15(8):2928-38. PubMed ID: 9256137
[TBL] [Abstract][Full Text] [Related]
16. Nilutamide: an antiandrogen for the treatment of prostate cancer.
Dole EJ; Holdsworth MT
Ann Pharmacother; 1997 Jan; 31(1):65-75. PubMed ID: 8997470
[TBL] [Abstract][Full Text] [Related]
17. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.
See WA; Tyrrell CJ;
J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S7-16. PubMed ID: 16896884
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
19. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
[TBL] [Abstract][Full Text] [Related]
20. Bicalutamide versus flutamide in combination therapy.
Labrie F; Candas B
Urology; 1999 Mar; 53(3):662-3. PubMed ID: 10096411
[No Abstract] [Full Text] [Related]
[Next] [New Search]
